Data from experimental models show that FABP1 silencing results in intrahepatic TAG accumulation and the development of liver disease [35], while FABP1 can also act as a transcription factor activating genes contributing to TAG accumulation [36]. The gene discussed is FABP1; the disease is liver disorder.